Skip to main content
SpringerLink
Log in

What’s New in Medical Management of Glaucoma

  • Chapter
  • First Online:
Glaucoma

Part of the book series: Current Practices in Ophthalmology ((CUPROP))

  • 988 Accesses

Abstract

Glaucoma mangement entails use of effective treatment modalities to not only lower but also to maintain intraocular pressure. This chapter reviews the current literature regarding existing pharmacotherapies for glaucoma and those in pipeline.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123(2):186–92.

    Article  CAS  Google Scholar 

  2. Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008;18(3):408–16.

    Article  CAS  Google Scholar 

  3. Selen F, Tekeli O, Yanik O. Assessment of the anterior chamber flare and macular thickness in patients treated with topical antiglaucomatous drugs. J Ocul Pharmacol Ther. 2017;33(3):170–5.

    Article  CAS  Google Scholar 

  4. Russo A, Riva I, Pizzolante T, et al. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol. 2008;2(4):897–905.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126(4):602–4.

    Article  CAS  Google Scholar 

  6. Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29(9):1800–10.

    Article  Google Scholar 

  7. Abe RY, Zacchia RS, Santana PR, Costa VP. Effects of benzalkonium chloride on the blood-aqueous and blood retinal barriers of pseudophakic eyes. J Ocul Pharmacol Ther. 2014;30(5):413–8.

    Article  CAS  Google Scholar 

  8. Razeghinejad MR. The effect of latanaprost on intraocular inflammation and macular edema. Ocul Immunol Inflamm. 2019;27:181–8.

    Article  CAS  Google Scholar 

  9. Ohtani S, Shimizu K, Nejima R, Kagaya F, Aihara M, Iwasaki T, Shoji N, Miyata K. Conjunctival bacteria flora of glaucoma patients during long-term administration of Prostaglandin analog drops. Invest Ophthalmol Vis Sci. 2017;58(10):3991–6.

    Article  CAS  Google Scholar 

  10. Saji M, Usuki R, Ibaraki N, Hayam N, Osono E, Ohkuni H. Studies of antibacterial activity of benzalkonium chloride as preservative for ophthalmic solutions against gram-positive cocci and negative rods. Jpn J Pharm Health Care Sci. 2003;29:341–5.

    Article  CAS  Google Scholar 

  11. Kurihara T, Sugita M, Motai S, Kurashige S. In vitro induction of chlorhexidine- and benzalkonium-resistance in clinically isolated Pseudomonas aeruginosa [in Japanese]. Kansenshogaku Zasshi. 1993;67:202–6.

    Article  CAS  Google Scholar 

  12. Cunniffe MG, Medel-Jiménez R, González-Candial M. Topical antiglaucoma treatment with prostaglandin analogues may precipitate meibomian gland disease. Ophthal Plast Reconstr Surg. 2011;27:e128–9.

    Article  Google Scholar 

  13. Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. J Glaucoma. 2016;25(9):770–4.

    Article  Google Scholar 

  14. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93–105.

    Article  Google Scholar 

  15. Choi HY, Lee JE, Lee JW, Park HJ, Lee JE, Jung JH. Invitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadipocytes. J Ocul Pharmacol Ther. 2012;28:146Y52.

    Article  Google Scholar 

  16. Patradul C, Tantisevi V, Manassakorn A. Factors related to prostaglandin-associated periorbitopathy in glaucoma patients. Asia Pac J Ophthalmol (Phila). 2017;6(3):238–42.

    CAS  Google Scholar 

  17. Skorin L Jr, Dailey KH. Clicking eyelids: a new finding of prostaglandin-associated periorbitopathy. Optom Vis Sci. 2016;93(7):779–81.

    Article  Google Scholar 

  18. Fong CS, Rajak SN, Pirbhai A, Selva D. Audible blink in prostaglandin-associated periorbitopathy. Clin Experiment Ophthalmol. 2016;44(7):630–1.

    Article  Google Scholar 

  19. Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26(4):515–22.

    Article  Google Scholar 

  20. Choi YM, Diehl J, Levins PC. Promising alternative clinical use of prostaglandin F2α analogs: beyond the eyelashes. J Am Acad Dermatol. 2015;72(4):712–6.

    Article  CAS  Google Scholar 

  21. Mäenpää J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016;15(11):1549–61.

    Article  Google Scholar 

  22. Inoue T, Tanihara H. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. Expert Opin Pharmacother. 2017;18(15):1669–73.

    Article  CAS  Google Scholar 

  23. Sato S, Hirooka K, Nitta E, et al. Additive intraocular pressure lowering effects of the Rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33:1628–34.

    Article  CAS  Google Scholar 

  24. Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, dose response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122:302–7.

    Article  Google Scholar 

  25. Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. ROCKET-1 and ROCKET-2 Study Groups. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2018;186:116. pii: S0002-9394(17)30513-5.

    Article  CAS  Google Scholar 

  26. Schehlein EM, Novack GD, Robin AL. New classes of of glaucoma medications. Curr Opin Ophthalmol. 2017;28(2):161–8.

    PubMed  Google Scholar 

  27. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. for the VOYAGER Study Group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–45.

    Article  Google Scholar 

  28. Weinreb RN, Scassellati SB, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123:965–73.

    Article  Google Scholar 

  29. Vittitow JL, Liebmann JM, Kaufman PL, et al. Long-term efficacy and safety of latanoprostene bunod 0.024% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: APOLLO and LUNAR studies. Invest Ophthalmol Vis Sci. 2016;57(12):3030.

    Google Scholar 

  30. Kawase K, Vittitow JL, Weinreb RN, et al. for the JUPITER Study Group. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33:1612–27.

    Article  CAS  Google Scholar 

  31. Liu JHK, Slight JR, Vittitow JL, et al. Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours. Am J Ophthalmol. 2016;169:249–57.

    Article  CAS  Google Scholar 

  32. Martinez T, Jimenez AI, Paneda C. Short-interference RNAs: becoming medicines. EXCLI J. 2015;14:714–46.

    PubMed  PubMed Central  Google Scholar 

  33. Gonzalez V, Moreno-Montanes J, Oll M, et al. Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma. Poster session presented at Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO), Seattle, WA; 2016.

    Google Scholar 

  34. Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucl Acid Ther. 2014;24:258–66.

    Article  CAS  Google Scholar 

  35. Filippopoulos T, Ducharme JF, Loewenstein JI, Krzystolik MG. Antiangiogenic agents as an adjunctive treatment for complicated neovascular glaucoma. Invest Ophthalmol Vis Sci. 2006;47:4476.

    Article  Google Scholar 

  36. Bleau A-M, Vargas B, Jiménez AI, Pañeda C. Managing intraocular pressure: innovation in glaucoma management. In: Ichhpujani P, editor. Glaucoma - intraocular pressure and aqueous dynamics. Croatia: InTech; 2016. https://doi.org/10.5772/65972.

    Chapter  Google Scholar 

  37. Kalouche G, Beguier F, Bakria M, et al. Activation of prostaglandin FP and EP2 receptors differently modulates myofibroblast transition in a model of adult primary human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2016;57:1816–25.

    Article  CAS  Google Scholar 

  38. Ihekoromadu N, Lu F, Iwamura R, et al. Safety and efficacy of DE-117, a selective EP2 agonist in a Phase 2a study. Invest Ophthalmol Vis Sci. 2015;56:5708.

    Google Scholar 

  39. Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci. 2015;56:2547–52.

    Article  CAS  Google Scholar 

  40. Harris A, Ward CL, Rowe-Rendleman CL, et al. Ocular hypotensive effect of ONO-9054, an EP3/FP receptor agonist: results of a randomized, placebo controlled, dose escalation study. J Glaucoma. 2016;25:e826–33.

    Article  Google Scholar 

  41. Berlin MS, Rowe-Rendleman C, Ahmed I, et al. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol. 2016;100:843–7.

    Article  Google Scholar 

  42. Miller-Ellis EG, Berlin MS, Ward CL, Sharpe J, Jamil A, Harris A, et al. Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan1: results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT). Br J Opthalmol. 2017;101:796–800.

    Article  Google Scholar 

  43. Myers JS, Sall KN, DuBiner H, et al. A Dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2016;32(8):555–62.

    Article  CAS  Google Scholar 

  44. Schmeer C, Kretz A, Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci. 2006;24(2):79–95.

    CAS  PubMed  Google Scholar 

  45. Pokrovskaya O, Wallace D, O’Brien C. The emerging role of statins in glaucoma pathological mechanisms and therapeutics. Open J Ophthalmol. 2014;4:124–38.

    Article  Google Scholar 

  46. McCann P, Hogg RE, Fallis R, Azuara-Blanco A. The effect of statins on intraocular pressure and on the incidence and progression of glaucoma: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2016;57(6):2729–48.

    Article  CAS  Google Scholar 

  47. Talwar N, Musch DC, Stein JD. Association of daily dosage and type of Statin agent with risk of Open-Angle Glaucoma. JAMA Ophthalmol. 2017;135(3):263–7.

    Article  Google Scholar 

  48. Brandt JD, Sall K, DuBiner H, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016;123:1685–94.

    Article  Google Scholar 

  49. Brandt JD, DuBiner HB, Benza R, Sall KN, Walker GA, Semba CP, Collaborators. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2017;124(10):1565–6.

    Article  Google Scholar 

  50. Lewis RA, Christie WC, Day DG, et al. Study Group. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase. I/II Clin Trial Am J Ophthalmol. 2017;175:137–47.

    CAS  Google Scholar 

  51. Ciolino JB, Ross AE, Tulsan R, et al. Latanoprost-eluting contact lenses in glaucomatous monkeys. Ophthalmology. 2016;123:2085–92.

    Article  Google Scholar 

  52. Envisia Therapeutics. Releases ENV515 (travoprost XR) Phase 2 data showing nine-month duration of action after a single dose in patients with glaucoma. Triangle Park, NC: Envisia Therapeutics; 2016. https://www.prnewswire.com/news-releases/envisia-therapeutics-releases-env515-travoprost-xr-phase-2-data-showing-nine-month-duration-of-action-after-a-single-dose-in-patients-with-glaucoma-300345633.html.

    Google Scholar 

  53. Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol (Auckland, NZ). 2016;10:757–64.

    Article  CAS  Google Scholar 

  54. Mati Therapeutics. Mati Therapeutics selected to present at Ocular Innovation Summit: pursuing sustained ocular drug delivery programs in inflammation, pain, and glaucoma, 3 October. Austin, TX: Mati Therapeutics; 2016. Accessed Jan 2018. Available at www.matitherapeutics.com/about/press/ocular-innovation-summit.

    Google Scholar 

  55. www.psivida.com/products.html. Accessed 13 Jan 2018.

  56. www.replenishinc.com. Accessed 13 Jan 2018.

  57. http://www.oraclinical.com/articles/euclid-systems-partners-ora-inc-development-its-novel-collagen-based-drug-delivery-system. Accessed 13 Jan 2018.

  58. Lavik E, Kuehn MH, Shoffstall AJ, Atkins K, Dumitrescu AV, Kwon YH. Sustained delivery of timolol maleate for over 90 days by subconjunctival injection. J Ocul Pharmacol Ther. 2016;32(10):642–9.

    Article  CAS  Google Scholar 

  59. Di Zazzo A, Roberti G, Mashaghi A, Abud TB, Pavese D, Bonini S. Use of topical cannabinomimetic palmitoylethanolamide in ocular surface disease associated with antiglaucoma medications. J Ocul Pharmacol Ther. 2017;33(9):670–7.

    Article  Google Scholar 

  60. Gipson IK. Goblet cells of the conjunctiva: a review of recent findings. Prog Retin Eye Res. 2016;54:49–63.

    Article  Google Scholar 

  61. Kawaguchi I, Kobayashi A, Higashide T, Takeji Y, Sakurai K, Kawaguchi C, Sugiyama K. Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits. PLoS One. 2017;12(10):e0186714.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Glaucoma Service, Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India

    Parul Ichhpujani

Authors
  1. Parul Ichhpujani
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India

    Parul Ichhpujani

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ichhpujani, P. (2019). What’s New in Medical Management of Glaucoma. In: Ichhpujani, P. (eds) Glaucoma. Current Practices in Ophthalmology. Springer, Singapore. https://doi.org/10.1007/978-981-13-8457-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-8457-8_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-8456-1

  • Online ISBN: 978-981-13-8457-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation